tiprankstipranks
Needham adds Axsome to Conviction List, removes Blueprint
PremiumThe FlyNeedham adds Axsome to Conviction List, removes Blueprint
2M ago
Blueprint Medicines initiated with an Overweight at JPMorgan
Premium
The Fly
Blueprint Medicines initiated with an Overweight at JPMorgan
2M ago
Cogent selloff on ‘old news’ is ‘unwarranted,’ says Citi
Premium
The Fly
Cogent selloff on ‘old news’ is ‘unwarranted,’ says Citi
2M ago
Blueprint management moves maybe made with buyer in mind, says Oppenheimer
PremiumThe FlyBlueprint management moves maybe made with buyer in mind, says Oppenheimer
3M ago
Blueprint Medicines reports Q3 EPS (89c), consensus (96c)
Premium
The Fly
Blueprint Medicines reports Q3 EPS (89c), consensus (96c)
3M ago
Blueprint Medicines sees FY24 global AYVAKIT net product revenues $475M-$480M
Premium
The Fly
Blueprint Medicines sees FY24 global AYVAKIT net product revenues $475M-$480M
3M ago
Blueprint Medicines raises 2024 product revenues view to $435M-$450M
PremiumThe FlyBlueprint Medicines raises 2024 product revenues view to $435M-$450M
6M ago
Blueprint Medicines reports Q2 EPS (80c), consensus ($1.29)
Premium
The Fly
Blueprint Medicines reports Q2 EPS (80c), consensus ($1.29)
6M ago
Is BPMC a Buy, Before Earnings?
Premium
Pre-Earnings
Is BPMC a Buy, Before Earnings?
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100